Lynne Jesaitis BioMarin Pharmaceutical Inc Biography Publications Institution JoVE Articles Lynne Jesaitis has not added a biography. If you are Lynne Jesaitis and would like to personalize this page please email our Author Liaison for assistance. Publications Safety, Immunogenicity, and Clinical Outcomes in Patients with Morquio A Syndrome Participating in 2 Sequential Open-label Studies of Elosulfase Alfa Enzyme Replacement Therapy (MOR-002/MOR-100), Representing 5 years of Treatment Molecular Genetics and Metabolism. Apr, 2018 | Pubmed ID: 29526614 Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study Clinical Therapeutics. Jan, 2017 | Pubmed ID: 27955919 Antibodies That Neutralize Cellular Uptake of Elosulfase Alfa Are Not Associated with Reduced Efficacy or Pharmacodynamic Effect in Individuals with Morquio A Syndrome Journal of Immunological Methods. 01, 2017 | Pubmed ID: 27789297 Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial Clinical Therapeutics. May, 2015 | Pubmed ID: 25487082 Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome Clinical Pharmacokinetics. Dec, 2014 | Pubmed ID: 25234648 Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay Ruby Cheung1, Gregory W. deHart1, Lynne Jesaitis1, Stephen J. Zoog1, Andrew C. Melton1 1BioMarin Pharmaceutical Inc JoVE 57777 Imunologia e Infecção
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay Ruby Cheung1, Gregory W. deHart1, Lynne Jesaitis1, Stephen J. Zoog1, Andrew C. Melton1 1BioMarin Pharmaceutical Inc JoVE 57777 Imunologia e Infecção